Klotho Neurosciences, Inc.(KLTO)Earnings, Financials & Key Ratios
KLTO•NASDAQ
Price updated May 1, 2026
AboutKlotho Neurosciences, Inc., a biopharmaceutical company, develops medicines for the treatment of cancer, cardiovascular, and neurodegenerative disorders. Its lead gene therapy product candidates include AMI-101 for the treatment or prevention of Alzheimer's disease; and AMI-202 to treat and prevent amyotrophic lateral sclerosis. The company was formerly known as Anew Medical, Inc. and changed its name to Klotho Neurosciences, Inc. in September 2024. The company is based in Omaha, Nebraska.Show more
- Revenue$0
- EBITDA-$6M-817.8%
- Net Income-$6M-769.4%
- EPS (Diluted)-0.32-45614.3%
- ROE-700.07%-766.3%
- ROIC-242.32%-1048.2%
- Debt/Equity0.23-91.1%
- Interest Coverage-15.54-87.6%
KLTO Key Insights
Klotho Neurosciences, Inc. (KLTO) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Share count reduced 98.2% through buybacks
✗Weaknesses
- ✗Low quality earnings: Net income not backed by cash flow
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when KLTO posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
KLTO Price & Volume
Klotho Neurosciences, Inc. (KLTO) stock price & volume — 10-year historical chart
Loading chart...
KLTO Growth Metrics
Klotho Neurosciences, Inc. (KLTO) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-168.2%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-49.77%
Return on Capital
10 Years-213.55%
5 Years-213.55%
3 Years-248.72%
Last Year-621.96%
KLTO Peer Comparison
Klotho Neurosciences, Inc. (KLTO) competitors in Cell and Gene Therapy Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 SAVA | 63.77M | 1.32 | -2.54 | -95.77% | ||||
 NRXP | 66.38M | 3.84 | -2.87 | -10.7% | ||||
 ACIU | 235.1M | 2.31 | -2.63 | -86.92% | -19.69% | -101.6% | 0.10 | |
 PRAX | 7.7B | 266.54 | -19.77 | -100% | -43.02% | 0.00 | ||
 ATHA | 17.12M | 4.34 | -0.17 | -381.01% | 0.03 | |||
 BIIB | 29.53B | 200.05 | 22.66 | 1.39% | 13.92% | 7.55% | 0.38 | |
 ESPR | 654.91M | 3.15 | -28.64 | 21.31% | -1.77% | |||
 AVXL | 231.68M | 2.50 | -4.63 | -38.76% |
Compare KLTO vs Peers
Klotho Neurosciences, Inc. (KLTO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
KLTO Income Statement
Klotho Neurosciences, Inc. (KLTO) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 0 |
Revenue Growth % | - | - | - | - | - |
Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 |
COGS % of Revenue | - | - | - | - | - |
Gross Profit | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% |
Gross Margin % | - | - | - | - | - |
Gross Profit Growth % | - | - | - | - | - |
Operating Expenses | 1.11M | 574.37K | 631.32K | 5.54M | 7.18M |
OpEx % of Revenue | - | - | - | - | - |
Selling, General & Admin | 1.11M | 574.37K | 631.32K | 5.54M | 6.67M |
SG&A % of Revenue | - | - | - | - | - |
Research & Development | 0 | 0 | 0 | 0 | 509.85K |
R&D % of Revenue | - | - | - | - | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 |
Operating Income | -1.11M▲ 0% | -574.37K▲ 48.2% | -631.32K▼ 9.9% | -5.54M▼ 777.6% | -7.18M▲ 0% |
Operating Margin % | - | - | - | - | - |
Operating Income Growth % | - | 48.21% | -9.91% | -777.56% | - |
EBITDA | -1.11M | -574.23K | -631.24K | -5.79M | -7.5M |
EBITDA Margin % | - | - | - | - | - |
EBITDA Growth % | - | 48.22% | -9.93% | -817.83% | -81.47% |
D&A (Non-Cash Add-back) | 0 | 0 | 0 | 0 | 0 |
EBIT | -1.11M | -574.23K | -631.24K | -5.79M | -7.5M |
Net Interest Income | 0 | -24.37K | -76.21K | -356.6K | -3.79M |
Interest Income | 0 | 0 | 0 | 0 | 0 |
Interest Expense | 0 | 24.37K | 76.21K | 356.6K | 3.79M |
Other Income/Expense | 44 | -24.22K | -76.14K | -610.14K | -4.11M |
Pretax Income | -1.11M▲ 0% | -598.59K▲ 46.0% | -707.46K▼ 18.2% | -6.15M▼ 769.4% | -11.29M▲ 0% |
Pretax Margin % | - | - | - | - | - |
Income Tax | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% |
Net Income | -1.11M▲ 0% | -598.59K▲ 46.0% | -707.46K▼ 18.2% | -6.15M▼ 769.4% | -11.29M▲ 0% |
Net Margin % | - | - | - | - | - |
Net Income Growth % | - | 46.03% | -18.19% | -769.36% | -168.2% |
Net Income (Continuing) | -1.11M | -598.59K | -707.46K | -6.15M | -11.29M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.00▲ 0% | -0.00▲ 45.5% | -0.00▼ 16.7% | -0.32▼ 45614.3% | -0.19▲ 0% |
EPS Growth % | - | - | - | - | -49.77% |
EPS (Basic) | -0.00 | -0.00 | -0.00 | -0.32 | - |
Diluted Shares Outstanding | 1.04B | 1.04B | 1.04B | 19.25M | 59.42M |
Basic Shares Outstanding | 1.04B | 1.04B | 1.04B | 19.25M | 59.42M |
Dividend Payout Ratio | - | - | - | - | - |
KLTO Balance Sheet
Klotho Neurosciences, Inc. (KLTO) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|
Total Current Assets | 304.52K | 329.54K | 6.65K | 157.81K | 7.77M |
Cash & Short-Term Investments | 300.85K | 75.87K | 2.81K | 63.74K | 7.35M |
Cash Only | 300.85K | 75.87K | 2.81K | 63.74K | 7.35M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 0 | 0 | 0 | 0 | 339.25K |
Days Sales Outstanding | - | - | - | - | - |
Inventory | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - |
Other Current Assets | 0 | 250K | 0 | 0 | 0 |
Total Non-Current Assets | 736.98K | 2.21M | 2.19M | 2.3M | 2.3M |
Property, Plant & Equipment | 0 | 0 | 0 | 0 | 0 |
Fixed Asset Turnover | - | - | - | - | - |
Goodwill | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 736.98K | 2.21M | 2.19M | 2.3M | 2.3M |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 1.04M▲ 0% | 2.54M▲ 143.8% | 2.19M▼ 13.7% | 2.46M▲ 12.1% | 10.07M▲ 0% |
Asset Turnover | - | - | - | - | 0.00x |
Asset Growth % | - | 143.83% | -13.65% | 12.07% | 576.14% |
Total Current Liabilities | 15.13K | 1.36M | 1.62M | 1.25M | 92.89K |
Accounts Payable | 15.13K | 8.01K | 151.26K | 63.69K | 0 |
Days Payables Outstanding | - | - | - | - | - |
Short-Term Debt | 0 | 1.35M | 1.47M | 271.75K | 0 |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 92.89K |
Current Ratio | 20.12x | 0.24x | 0.00x | 0.13x | 83.69x |
Quick Ratio | 20.12x | 0.24x | 0.00x | 0.13x | 83.69x |
Cash Conversion Cycle | - | - | - | - | - |
Total Non-Current Liabilities | 0 | 0 | 0 | 24.49K | 53K |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 24.49K | 53K |
Total Liabilities | 15.13K | 1.36M | 1.62M | 1.27M | 145.89K |
Total Debt | 0 | 1.35M | 1.47M | 271.75K | 0 |
Net Debt | -300.85K | 1.27M | 1.46M | 208.01K | -7.35M |
Debt / Equity | - | 1.14x | 2.57x | 0.23x | 0.00x |
Debt / EBITDA | - | - | - | - | -0.00x |
Net Debt / EBITDA | - | - | - | - | 0.98x |
Interest Coverage | - | -23.57x | -8.28x | -15.54x | -1.98x |
Total Equity | 1.03M▲ 0% | 1.18M▲ 14.9% | 571.72K▼ 51.5% | 1.19M▲ 107.3% | 9.93M▲ 0% |
Equity Growth % | - | 14.89% | -51.52% | 107.33% | 1550.94% |
Book Value per Share | 0.00 | 0.00 | 0.00 | 0.06 | 0.17 |
Total Shareholders' Equity | 1.03M | 1.18M | 571.72K | 1.19M | 9.93M |
Common Stock | 104.49K | 104.49K | 1.51K | 2.71K | 7.03K |
Retained Earnings | -2.62M | -3.22M | -3.92M | -10.56M | -19.79M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | 751.4K | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
KLTO Cash Flow Statement
Klotho Neurosciences, Inc. (KLTO) cash flow — operating, investing & free cash flow history
| Metric | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|
Cash from Operations | -284.02K | -599.57K | -446.92K | -2.95M | -5.55M |
Operating CF Margin % | - | - | - | - | - |
Operating CF Growth % | - | -111.1% | 25.46% | -559.3% | -7708.17% |
Net Income | -1.11M | -598.59K | -707.46K | -6.15M | -11.29M |
Depreciation & Amortization | 0 | 0 | 0 | 0 | 0 |
Stock-Based Compensation | 821.15K | 1.4K | 0 | 2.65M | 495.5K |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 0 | 0 | 0 | 403.71K | 5.83M |
Working Capital Changes | 3.85K | -2.38K | 260.54K | 150.57K | -587.04K |
Change in Receivables | 0 | 0 | 0 | 0 | 0 |
Change in Inventory | 0 | 0 | 0 | 0 | 0 |
Change in Payables | -12.9K | -7.12K | 104K | -187.57K | 2.86K |
Cash from Investing | 0 | -125.41K | 23.85K | -123.5K | 0 |
Capital Expenditures | 0 | -125.41K | -13.89K | -123.5K | 0 |
CapEx % of Revenue | - | - | - | - | - |
Acquisitions | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - |
Other Investing | 0 | 0 | 37.74K | 0 | 0 |
Cash from Financing | 250K | 500K | 350K | 3.13M | 12.85M |
Debt Issued (Net) | 0 | -8.51K | 159K | 2.18M | 591.29K |
Equity Issued (Net) | 250K | 750K | 100K | 175K | 1.13M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | -120K | 0 |
Other Financing | 0 | -241.49K | 91K | 778.94K | -259.13K |
Net Change in Cash | -34.02K▲ 0% | -224.98K▼ 561.3% | -73.06K▲ 67.5% | 60.93K▲ 183.4% | 7.3M▲ 0% |
Free Cash Flow | -284.02K▲ 0% | -724.98K▼ 155.3% | -460.8K▲ 36.4% | -3.07M▼ 566.2% | -5.55M▲ 0% |
FCF Margin % | - | - | - | - | - |
FCF Growth % | - | -155.26% | 36.44% | -566.23% | -201.42% |
FCF per Share | -0.00 | -0.00 | -0.00 | -0.16 | -0.09 |
FCF Conversion (FCF/Net Income) | 0.26x | 1.00x | 0.63x | 0.48x | 0.49x |
Interest Paid | 0 | 19.62K | 78.5K | 2.46K | 0 |
Taxes Paid | 0 | 0 | 0 | 551.59K | 0 |
KLTO Key Ratios
Klotho Neurosciences, Inc. (KLTO) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|
| Return on Equity (ROE) | -54.28% | -80.81% | -700.07% | -113.73% |
| Return on Invested Capital (ROIC) | -27.12% | -21.11% | -242.32% | -268.33% |
| Debt / Equity | 1.14x | 2.57x | 0.23x | 0.00x |
| Interest Coverage | -23.57x | -8.28x | -15.54x | -1.98x |
| FCF Conversion | 1.00x | 0.63x | 0.48x | 0.49x |
Related:KLTO Dividend History·KLTO Revenue History·KLTO Price History·KLTO P/E History·KLTO Financial Ratios·KLTO Institutional Holders
KLTO Frequently Asked Questions
Klotho Neurosciences, Inc. (KLTO) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Klotho Neurosciences, Inc. (KLTO) grew revenue by 0.0% over the past year. Growth has been modest.
Klotho Neurosciences, Inc. (KLTO) reported a net loss of $11.3M for fiscal year 2024.
Dividend & Returns
Klotho Neurosciences, Inc. (KLTO) has a return on equity (ROE) of -700.1%. Negative ROE indicates the company is unprofitable.
Klotho Neurosciences, Inc. (KLTO) had negative free cash flow of $5.6M in fiscal year 2024, likely due to heavy capital investments.